Physician profile
Brian Pierce
NPI 1538515457
$930.44
in general payments reported to CMS, 2019-2025
17 companies · $69.65 in 2025
The $69.65 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $249 · 2023: $83.55 · 2024: $171 · 2025: $69.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.16 | 2021-2024 | |
| Pfizer INC. | $116.37 | 2021 | |
| Allergan, INC. | $86.90 | 2021-2022 | |
| Novo Nordisk INC | $71.75 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $71.53 | 2021-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $64.26 | 2021-2022 | |
| Edwards Lifesciences Corporation | $53.22 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $36.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.75 | 2023 | |
| Horizon Therapeutics Plc | $18.22 | 2022 | |
| Merck Sharp & Dohme LLC | $17.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.62 | 2021 | |
| Amgen INC. | $16.43 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $14.85 | 2024 | Airsupra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.21 | 2021 | |
| Genentech USA, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.